Contents
Drug competition and voluntary exit
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Virabhak, Suchin | - |
| dc.contributor.author | Sohn, Wook | - |
| dc.date.available | 2018-12-06T04:46:01Z | - |
| dc.date.created | 2017-12-29 | - |
| dc.date.issued | 2008-10 | - |
| dc.identifier.issn | 0165-1765 | - |
| dc.identifier.uri | http://archives.kdischool.ac.kr/kdi_dev/handle/11125/28784 | - |
| dc.identifier.uri | 10.1016/j.econlet.2008.04.001 | - |
| dc.description.abstract | We use a duration model to find evidence that drug exit is exacerbated by generic competition. However, the impact on drug exit of competition with other branded drugs within a drug's therapeutic class is not statistically significant. (C) 2008 Elsevier B.V. All rights reserved. | - |
| dc.language | English | - |
| dc.publisher | ELSEVIER SCIENCE SA | - |
| dc.subject | PHARMACEUTICALS | - |
| dc.subject | ACT | - |
| dc.title | Drug competition and voluntary exit | - |
| dc.type | Article | - |
| dc.identifier.bibliographicCitation | ECONOMICS LETTERS, v.101, no.1, pp.34 - 37 | - |
| dc.description.journalClass | 1 | - |
| dc.description.isOpenAccess | N | - |
| dc.identifier.wosid | 000259731300011 | - |
| dc.citation.endPage | 37 | - |
| dc.citation.number | 1 | - |
| dc.citation.startPage | 34 | - |
| dc.citation.title | ECONOMICS LETTERS | - |
| dc.citation.volume | 101 | - |
| dc.contributor.affiliatedAuthor | Sohn, Wook | - |
| dc.identifier.doi | 10.1016/j.econlet.2008.04.001 | - |
| dc.identifier.scopusid | 2-s2.0-49949115558 | - |
| dc.type.docType | Article | - |
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Click the button and follow the links to connect to the full text. (KDI CL members only)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.